Polestar to Launch Polestar 4 Pure EV in South Korea 
Economists say Australia shouldn’t try to transition to net zero by aping the mammoth US Inflation Reduction Act 
Industry shutdowns are messy and painful: 4 lessons Australia’s coal sector can learn from car-makers about bowing out 
Taeyoung to Sack Executives, Cut Employees' Salaries to Save Company 
Online wellness content: 3 ways to tell evidence-based health information from pseudoscience 
How cuts to marginal income tax could boost the UK’s stagnant economic growth 
Tapeworm larvae found in man’s brain – how did they get there? 
Meta AI to Supercharge WhatsApp, Facebook, Instagram via Powerful Integration 
Honey is said to help with hay fever symptoms – here’s what the research says about this claim 
SPC Group’s Paris Baguette Inaugurates First Bakery Shop in the Philippines 
Eye infections might seem like a minor complaint – but in some cases they can cause blindness and even death 
Coca-Cola Launches Global 'Recycle Me' Campaign to Champion Recycling 
Google Fired Workers Protesting Over Cloud Contract Deal With Israel 
Boxers, briefs and bacterial vaginosis: how your underwear can affect your health 
Fujirebio Holding is now doubling down on developing blood tests to detect Alzheimer’s against which blockbuster therapy is expected soon.
The tiny Tokyo-based diagnostics firm, a unit of H.U. Group Holdings, which has a market value of $1.2 billion, developed the first US-approved spinal fluid test for Alzheimer’s.
According to Goki Ishikawa, the CEO of Fujirebio, the firm is boosting its lineup of reagents used to detect Alzheimer’s biomarkers in blood tests. It aims to file these tests for approval in the US as early as 2023.
Ishikawa said that the lineups offered by industry leaders are still limited, so they are rushing to create a solid lineup of tests.
